Sanuwave Health Inc. (NASDAQ:SNWV) Short Interest Down 45.8% in August

Sanuwave Health Inc. (NASDAQ:SNWV) was the target of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 304,527 shares, a decline of 45.8% from the July 30th total of 561,489 shares. Based on an average daily trading volume, of 109,529 shares, the short-interest ratio is presently 2.8 days. Currently, 4.1% of the shares of the company are sold short.

Analysts Set New Price Targets

Separately, Weiss Ratings lowered Sanuwave Health from a “hold (c)” rating to a “hold (c-)” rating in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, one has assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $51.00.

Hedge Funds Weigh In On Sanuwave Health

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc acquired a new stake in shares of Sanuwave Health in the second quarter valued at about $26,000. Charles Schwab Investment Management Inc. lifted its stake in Sanuwave Health by 4.9% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 24,398 shares of the company’s stock valued at $728,000 after buying an additional 1,135 shares in the last quarter. Bank of America Corp DE lifted its stake in Sanuwave Health by 4.9% in the 1st quarter. Bank of America Corp DE now owns 25,503 shares of the company’s stock valued at $441,000 after buying an additional 1,182 shares in the last quarter. Barclays PLC boosted its holdings in Sanuwave Health by 12.7% in the 4th quarter. Barclays PLC now owns 11,610 shares of the company’s stock worth $346,000 after buying an additional 1,306 shares during the last quarter. Finally, BNP Paribas Financial Markets purchased a new stake in Sanuwave Health during the 2nd quarter worth approximately $46,000. 42.53% of the stock is currently owned by institutional investors and hedge funds.

Sanuwave Health Stock Performance

SNWV traded down $0.06 on Tuesday, reaching $4.63. The stock had a trading volume of 5,334 shares, compared to its average volume of 122,915. The company has a current ratio of 1.28, a quick ratio of 0.89 and a debt-to-equity ratio of 4.87. Sanuwave Health has a 12-month low of $4.50 and a 12-month high of $41.90. The business’s 50-day moving average price is $7.09 and its two-hundred day moving average price is $14.50. The company has a market cap of $39.86 million, a P/E ratio of 19.32 and a beta of 1.48.

Sanuwave Health (NASDAQ:SNWV) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.05). The business had revenue of $9.74 million during the quarter, compared to analyst estimates of $11.50 million. Sanuwave Health had a return on equity of 1,728.10% and a net margin of 32.38%.

Sanuwave Health Company Profile

Sanuwave Health, Inc is a medical technology company specializing in the development and commercialization of non-invasive acoustic wave therapies designed to stimulate tissue regeneration and accelerate healing. The company’s proprietary Extracorporeal Pulse Activated Technology (EPAT) delivers focused acoustic pressure waves to injured or chronic wound sites, activating the body’s natural repair mechanisms. Sanuwave’s primary therapeutic areas include advanced wound care for diabetic and venous ulcers, as well as orthopedic and musculoskeletal conditions.

The company’s lead product, the dermaPACE® system, holds clearance from the U.S.